Affinage

PAX5

Paired box protein Pax-5 · UniProt Q02548

Length
391 aa
Mass
42.1 kDa
Annotated
2026-06-10
100 papers in source corpus 49 papers cited in narrative 49 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PAX5 (BSAP) is a paired-domain transcription factor that serves as the master regulator of B-cell identity throughout lymphopoiesis, where it is both required to commit progenitors to the B lineage and continuously required to maintain that identity in mature B cells (PMID:8001127, PMID:11420047). Its N-terminal paired domain is necessary and sufficient for sequence-specific DNA binding, with three residues at positions 42, 44 and 47 determining its target specificity relative to other Pax proteins (PMID:1516825, PMID:7739566). PAX5 functions both as a direct activator of B-lineage genes — CD19, mb-1/Igα, N-myc, LEF-1, and the surrogate light-chain genes Igll1/Vpreb1 — and as a repressor of lineage-inappropriate and plasma-cell programs, repressing Notch1 to block T-cell development and repressing PRDM1/Blimp1 in an autoregulatory loop that restrains plasma-cell differentiation (PMID:1375324, PMID:9545244, PMID:12479824, PMID:17682124, PMID:39179932). Acute in vivo degradation establishes that PAX5 acts predominantly as a transcriptional activator that induces open chromatin at target genes, directly activating Rag1, Rag2, Dntt, Irf4 and Irf8 (PMID:39179932). Mechanistically, PAX5 operates as a cell-type-specific docking platform: it recruits Ets-family proteins (Ets-1, Net, Elk-1, Fli-1) into ternary complexes on the mb-1 promoter, cooperates with EBF, E2A and AML1, recruits Groucho/Grg4 corepressors through its octapeptide motif, and contacts the basal machinery via TBP and Rb (PMID:8804314, PMID:10197586, PMID:10455134, PMID:10811620, PMID:12446773, PMID:14500810). It orchestrates antigen-receptor assembly by inducing large-scale IgH locus contraction to enable distal VH-DJH recombination — repressing the cohesin-release factor Wapl to sustain loop extrusion — and by directly interacting with the RAG1-RAG2 complex to enhance V(D)J cleavage (PMID:15004008, PMID:16680144, PMID:39179932). In mature B cells PAX5 sustains BCR signaling and posttranscriptionally restrains PTEN to promote PI3K-AKT signaling (PMID:17717600, PMID:34301800). PAX5 also functions outside the B lineage, forming a core network with OCT4 and PRDM1 to drive human primordial germ-cell specification (PMID:29713018). In leukemia, PAX5 fusion proteins act as dominant-negatives via DNA-binding-domain multimerization, the PAX5-JAK2 fusion drives B-ALL by phosphorylating nuclear STAT5, and the PAX5 P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance (PMID:21765475, PMID:36516256, PMID:35156727). Biallelic loss-of-function PAX5 mutations cause human hypogammaglobulinemia with cerebellar and midbrain neurodevelopmental defects (PMID:35947077).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1992 High

    Establishing the molecular identity of BSAP answered whether a single factor underlies B-cell-specific gene regulation, defining PAX5 as a paired-domain transcription factor with intrinsic DNA-binding specificity and a bona fide B-lineage target.

    Evidence Biochemical purification, cDNA cloning and EMSA; in vivo footprinting and reporter assays on the CD19 promoter

    PMID:1375324 PMID:1516825

    Open questions at the time
    • Did not define the full target gene network
    • No structural basis for specificity yet
  2. 1994 High

    Germline knockout answered where PAX5 acts in development, showing it is essential for progression past the early pro-B stage and also patterns the posterior midbrain, revealing a non-redundant role at a developmental checkpoint.

    Evidence Pax5 knockout mouse with histology and flow cytometry; antisense knockdown and overexpression proliferation assays

    PMID:7511679 PMID:8001127

    Open questions at the time
    • Did not identify the direct target genes mediating the block
    • Mechanism of midbrain patterning unresolved
  3. 1995 High

    Domain dissection answered how DNA-binding specificity is encoded, identifying three paired-domain residues that switch specificity and showing PAX5 can repress by competing for overlapping Ets sites.

    Evidence In vitro mutagenesis of paired-domain fusion proteins, EMSA, transactivation assays; in vivo footprinting with triple-helix blocking at the IgH 3' enhancer

    PMID:7739566 PMID:7777508

    Open questions at the time
    • Repression of the 3' enhancer is Medium-confidence single-lab
    • No structural model of the paired domain-DNA complex
  4. 1996 High

    Identifying the transactivation domain and the Ets-docking function answered how PAX5 actively regulates transcription, defining it as a modular activator and a recruitment platform for partner factors.

    Evidence GAL4-fusion and reporter mutagenesis mapping the C-terminal transactivation domain; EMSA ternary-complex reconstitution with Ets proteins and selectivity mutagenesis on the mb-1 promoter

    PMID:8617244 PMID:8804314

    Open questions at the time
    • Endogenous coactivators recruited by the transactivation domain not defined
    • Ternary complexes shown in vitro/reporter, not at native chromatin
  5. 1998 High

    Inducible reconstitution in null cells answered which genes PAX5 directly controls, distinguishing genes activated via docking from those requiring the transactivation domain, and revealing a concentration-dependent activator/repressor switch.

    Evidence Hormone-inducible BSAP-ER in Pax5-/- pre-BI cells with domain deletions; quantitative binding-affinity and motif-swap reporter assays; transgenic rescue of the pre-BCR signaling block

    PMID:9506950 PMID:9545244 PMID:9705955

    Open questions at the time
    • Affinity-threshold model is Medium-confidence single-lab
    • Identity of docked factors at mb-1/LEF-1 not established
  6. 2000 High

    Partner and corepressor mapping answered how PAX5 mechanistically represses and how it enters the nucleus, identifying Groucho/Grg4 recruitment via the octapeptide, antagonism of PU.1, and a defined importin-α1-binding NLS.

    Evidence Yeast two-hybrid, co-IP and domain mapping for Grg4 and PU.1; GST pulldown and GFP-fusion localization assays for the NLS (aa 195-201)

    PMID:10688639 PMID:10748034 PMID:10811620

    Open questions at the time
    • PU.1 antagonism is Medium-confidence single-lab
    • Full corepressor complex composition not defined
  7. 2001 High

    Conditional inactivation answered whether PAX5 is needed only for commitment or continuously, showing mature B cells lose B identity and dedifferentiate without it, establishing PAX5 as a maintenance factor.

    Evidence Cre-lox conditional knockout with expression profiling and flow cytometry

    PMID:11420047

    Open questions at the time
    • Did not resolve which targets are most critical for identity maintenance
  8. 2002 High

    Gain-of-function and partner studies answered how PAX5 enforces lineage choice, showing it represses Notch1 to suppress T-cell fate and engages Daxx/CBP for context-dependent regulation.

    Evidence Ikaros-locus Pax5 knockin with flow cytometry and expression analysis; yeast two-hybrid and co-IP for Daxx

    PMID:11799127 PMID:12479824

    Open questions at the time
    • Daxx coactivation/corepression switch is Medium-confidence single-lab
    • Notch1 repression mechanism at the locus not detailed
  9. 2004 High

    Locus-architecture studies answered how PAX5 enables distal antigen-receptor recombination, showing it induces IgH locus contraction and repositions the Igκ locus out of repressive nuclear compartments.

    Evidence Retroviral reconstitution in Pax5-/- pro-B cells with 3D FISH and VDJ recombination PCR; FISH nuclear localization of the Jκ locus

    PMID:15004008 PMID:15067064

    Open questions at the time
    • The pro-B-specific cofactor required for contraction was not identified
    • Molecular link between PAX5 and the contraction machinery unresolved at the time
  10. 2006 High

    Biochemical and genetic studies answered how PAX5 acts directly within V(D)J recombination and how it restrains plasma-cell fate, showing it binds VH coding regions and the RAG1-RAG2 complex to enhance cleavage and represses the Blimp-1/XBP-1 program.

    Evidence ChIP, EMSA, RAG1/2 co-IP and in vitro V(D)J recombination assay; Pax5 deletion and rescue in DT40 cells

    PMID:16546097 PMID:16680144

    Open questions at the time
    • Stoichiometry of the PAX5-RAG complex not defined
    • How PAX5 mechanistically enhances cleavage at the active site unresolved
  11. 2007 High

    Studies in lymphoma and EBV answered how PAX5 sustains malignant and viral B-cell programs, showing it maintains BCR/ITAM signaling for neoplastic growth, autoregulates PRDM1, and drives the EBV Wp transforming promoter.

    Evidence Inducible PAX5-ER, dominant-negative and shRNA approaches with expression profiling; ChIP and recombinant-EBV mutagenesis; EMSA/ChIP/reporter on PRDM1

    PMID:17626071 PMID:17682124 PMID:17717600

    Open questions at the time
    • Direct vs indirect maintenance of individual BCR components not fully parsed
  12. 2018 High

    Work in primordial germ cells answered whether PAX5 functions beyond the B lineage, showing it forms a core network with OCT4 and PRDM1 and switches OCT4 from a pluripotency to a germline program.

    Evidence ChIP-seq of OCT4 occupancy, genome-editing gain/loss-of-function, epistasis and xenograft engraftment in human PGCs

    PMID:29713018

    Open questions at the time
    • How PAX5 redirects OCT4 partner choice mechanistically not defined
  13. 2011 High

    Mechanistic dissection of leukemic fusions answered how PAX5 rearrangements drive disease, showing fusion-driven oligomerization of the DNA-binding domain produces dominant-negative, chromatin-locked competitors of wild-type PAX5.

    Evidence FRAP in living cells, in vitro DNA binding, and artificial oligomerization-domain fusions; PAX5-PML co-IP, ChIP and PML-NB disruption assays

    PMID:21217775 PMID:21765475

    Open questions at the time
    • PAX5-PML dual mechanism is Medium-confidence single-lab
    • Target genes most relevant to transformation not enumerated
  14. 2021 High

    Conditional and double-mutant studies answered how PAX5 supports mature-B-cell signaling, showing it posttranscriptionally restrains PTEN to enable PI3K-AKT signaling and opposes EBF1 at the Myc locus.

    Evidence Pax5 and Pten/Pax5 conditional and double-mutant mice with PI3K-AKT signaling and proliferation assays; ChIP-seq, ATAC-seq, CCA and CRISPR editing at the Myc locus

    PMID:33619557 PMID:34301800

    Open questions at the time
    • The specific PTEN-targeting microRNAs were not definitively identified
    • Mechanism of opposing EBF1/PAX5 occupancy at Myc not fully resolved
  15. 2022 High

    In vivo models of specific mutations answered how PAX5 alterations cause B-ALL and treatment resistance, showing the JAK2 fusion phosphorylates nuclear STAT5 and the P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance.

    Evidence Endogenous-locus Pax5-Jak2 knockin with domain mutagenesis and pSTAT5 readouts; genome-wide CRISPR and TF screens with P80R genome editing and ChIP/ATAC at CD58; P80R knockin disease model; refutation of Blimp1-mediated Pax5 repression requirement

    PMID:30643249 PMID:32780801 PMID:35156727 PMID:36516256

    Open questions at the time
    • Full set of nuclear pSTAT5 targets driving leukemogenesis not catalogued
    • How P80R remodels enhancer chromatin mechanistically not fully resolved
  16. 2024 High

    Acute protein degradation answered the long-standing question of PAX5's predominant regulatory mode without compensation, showing it acts mainly as an activator that opens chromatin at direct targets including Rag1/2, Dntt, Irf4/8 and surrogate light-chain genes, and represses Wapl to sustain Igh loop extrusion.

    Evidence dTAG acute degradation in mice with stage-resolved ATAC-seq, ChIP-seq and RNA-seq

    PMID:39179932

    Open questions at the time
    • Direct coactivators delivering chromatin opening not identified
    • Mechanism of Wapl repression at the molecular level not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PAX5 mechanistically couples to chromatin-remodeling and loop-extrusion machinery to open target genes and reposition antigen-receptor loci remains unresolved.
  • No defined PAX5-recruited remodeling complex
  • Direct link between PAX5 and cohesin/Wapl regulation undefined
  • Structural basis of PAX5-RAG and PAX5-Ets complexes on native chromatin lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003677 DNA binding 4 GO:0060090 molecular adaptor activity 3 GO:0003723 RNA binding 1
Localization
GO:0005634 nucleus 2 GO:0005654 nucleoplasm 2
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 4 R-HSA-168256 Immune System 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-162582 Signal Transduction 3
Partners
EBF1ETS1RAG1RB1RUNX1SPI1TBPTLE4

Evidence

Reading pass · 49 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1992 PAX5 encodes the transcription factor BSAP; the intact paired domain is both necessary and sufficient for DNA binding of BSAP, and its DNA-binding sequence specificity differs from the related Pax-1 protein. Biochemical purification, cDNA cloning, DNA binding studies (EMSA) Genes & development High 1516825
1992 BSAP (PAX5) directly binds a high-affinity site in the CD19 gene promoter (occupying it in vivo in B cells but not in plasma or HeLa cells) and confers B-cell specificity in reporter assays, establishing CD19 as a direct PAX5 transcriptional target. In vitro protein-DNA binding, in vivo footprinting, transient transfection reporter assays Molecular and cellular biology High 1375324
1994 Targeted disruption of Pax5 in mice completely blocks B cell development at an early pro-B (pre-BI) cell stage, defining an essential role for Pax5 in early B lymphopoiesis, and also causes abnormal patterning of the posterior midbrain. Germline gene targeting (knockout mouse), histology, flow cytometry Cell High 8001127
1994 BSAP is required for LPS-induced B cell proliferation; antisense-mediated suppression of BSAP reduced proliferation, and overexpression stimulated proliferation, identifying BSAP as a rate-limiting regulator of B cell proliferation. Antisense oligonucleotide knockdown, overexpression by transfection, proliferation assays The Journal of experimental medicine Medium 7511679
1994 BSAP binds the Iε promoter (forming complex 3) and is essential for LPS/IL-4-induced immunoglobulin germ-line epsilon transcription; a BSAP binding site from a heterologous promoter can substitute functionally for the epsilon-associated site. EMSA, transient transfection reporter assays (CAT) Journal of immunology Medium 8144891
1995 Three amino acids at positions 42, 44, and 47 of the paired domain N-terminal subdomain determine the difference in DNA-binding specificity between Pax-6 and BSAP (Pax-5); mutating these three Pax-6 residues to the corresponding BSAP residues completely switches binding specificity to BSAP. In vitro mutagenesis of fusion proteins, EMSA, transactivation assays Molecular and cellular biology High 7739566
1995 BSAP represses the immunoglobulin heavy chain 3' alpha enhancer by blocking binding of NF-αP (an Ets family member) to the adjacent αP element; triple-helix-forming oligonucleotide blocking of BSAP binding in vivo derepressed the αP footprint and increased endogenous IgH transcription. In vitro binding, in vivo footprinting, triple-helix oligonucleotide transfection, reporter assay Proceedings of the National Academy of Sciences Medium 7777508
1996 The C-terminal serine/threonine/proline-rich region of BSAP contains a 55-amino-acid transactivation domain that is active from promoter and enhancer positions; this domain is negatively regulated by adjacent extreme C-terminal sequences; both elements function as an independent module conserved in Pax-2 and Pax-8. In vitro mutagenesis, transient transfection reporter assays, GAL4 fusion assays The EMBO journal High 8617244
1996 Pax-5 (BSAP) functions as a cell-type-specific docking protein that recruits Ets proto-oncogene family proteins (Ets-1, Net, Elk-1 but not SAP1a) to form functional ternary complexes on the mb-1 promoter; complex assembly requires only the Pax-5 paired box and ETS DNA-binding domains; a single valine in the ETS domain of SAP1a versus aspartic acid in other Ets proteins determines selectivity. EMSA (ternary complex formation), mutagenesis, transient transfection reporter assays Genes & development High 8804314
1996 BSAP directly activates the human epsilon germline promoter through binding sites identified by EMSA, contributing to both IL-4-dependent induction and CD40-mediated up-regulation of epsilon germline transcription in human B cells. EMSA, luciferase reporter assays with site-directed mutation of BSAP binding site Journal of immunology Medium 9190940
1997 Pax5 is required for VH-to-DHJH rearrangement at the IgH locus in adult pro-B cells (~50-fold reduction) while DH-to-JH rearrangements occur at normal frequency; fetal and adult B lymphopoiesis have differential dependency on Pax5. Pax5 knockout mouse analysis, PCR-based rearrangement assays, transplantation experiments Genes & development High 9042861
1997 Overexpression of BSAP in a late B cell line suppressed Ig synthesis and reduced Blimp-1 expression, inhibiting differentiation to plasma cell phenotype; BSAP overexpression suppressed spontaneous appearance of high-Ig-secreting cells. Stable transfection, overexpression of BSAP expression plasmid, flow cytometry, Ig secretion assay Journal of immunology Medium 9120274
1997 Cooperation of Pax2 and Pax5 is essential for normal functioning of the organizing center at the midbrain-hindbrain junction: compound heterozygous Pax5/Pax2 mutant mice show severe midbrain-cerebellar defects, and biallelic loss of both factors deletes the entire posterior midbrain/cerebellum. Double-mutant mouse genetics (Pax5 knockout × Krd deletion of Pax2 locus), morphological analysis Proceedings of the National Academy of Sciences High 9159136
1998 Pax5 directly activates Ig-alpha (mb-1), N-myc, and LEF-1 genes and represses PD-1 in pro-B cells, as shown using a hormone-inducible BSAP-estrogen receptor fusion in Pax5-deficient pre-BI cells; the paired domain alone (without transactivation domain) was sufficient to restore mb-1 and LEF-1 expression, suggesting PAX5 acts as a docking protein for other factors at those genes. Hormone-inducible BSAP-ER fusion in Pax5-/- pre-BI cells, loss- and gain-of-function experiments, gene expression analysis The EMBO journal High 9545244
1998 BSAP activator motifs have ~20-fold higher binding affinity than repressor motifs; a concentration-dependent mechanism selectively targets BSAP activities such that at higher concentrations repressor functions are engaged, while at lower concentrations only activator functions are maintained. DNA binding affinity measurements, reporter assays with swapped activator/repressor motifs Science Medium 9506950
1998 Pax5 arrests B lymphopoiesis at a stage that is unresponsive to pre-BCR signaling; pre-BCR is stably expressed on Pax5-/- pre-BI cells but fails to signal; BCL2 overexpression does not rescue the block, indicating Pax5 has a role beyond survival signaling at this stage. Transgenic rescue experiments (Igmu, Igmu-Igbeta, bcl2 transgenes in Pax5-/- mice), in vitro culture assays The Journal of experimental medicine High 9705955
1999 The partial homeodomain of Pax5 directly binds TBP (the TATA-binding protein) and the underphosphorylated form of Rb in vivo (by co-immunoprecipitation) and in vitro; interaction with TBP links Pax5 to the basal transcription machinery via TFIID; Rb interaction is cell-cycle regulated. Co-immunoprecipitation, in vitro GST pulldown, mutagenesis mapping Cancer research Medium 10197586
1999 AML1 (CBFα2) physically interacts with the paired DNA-binding domain of BSAP/PAX5, and the two proteins synergistically activate the B-cell-specific blk promoter by more than 50-fold in transient transfection assays. In vitro binding assay, co-immunoprecipitation, transient transfection reporter assays The Journal of biological chemistry Medium 10455134
2000 Pax5 exerts transcriptional repression by recruiting Groucho-family corepressors: yeast two-hybrid identified Grg4 as a Pax5 partner; interaction involves the octapeptide motif and C-terminal domain of Pax5, and the Q and SP regions of Grg4; Grg4 efficiently represses Pax5 transcriptional activity in an octapeptide-dependent manner; this Pax/Groucho interaction is conserved in Drosophila. Yeast two-hybrid screen, co-immunoprecipitation, domain deletion analysis, transient transfection reporter assays, Drosophila functional assay The EMBO journal High 10811620
2000 BSAP/Pax5 directly interacts with PU.1 through their respective DNA-binding domains; BSAP represses PU.1 transactivation through the BSAP inhibitory domain (residues 358–385) targeting PU.1 transactivation residues 7–30; this repression can be reversed by the coactivator p300. Co-immunoprecipitation, EMSA, transient transfection reporter assays with domain deletion mutants Molecular and cellular biology Medium 10688639
2000 Nuclear translocation of Ref-1 (APE1) in response to oxidative stress (H2O2) in B lymphocytes transiently increases its nuclear levels and enhances BSAP/Pax5 DNA-binding activity; Ref-1 co-transfection increases Pax5 activation of the CD19 promoter 5–8-fold. Western blot, in situ immunocytochemistry, EMSA, co-transfection reporter assay Nucleic acids research Medium 10666449
2001 Conditional inactivation of Pax5 in mature B cells (via CD19-cre or Mx-cre) causes loss of B cell identity: downregulation of B cell-specific genes and surface antigens, and upregulation of non-B lymphoid genes, demonstrating Pax5 is continuously required to maintain B cell identity throughout B lymphopoiesis. Conditional knockout mouse (Cre-lox), gene expression analysis, flow cytometry Immunity High 11420047
2002 Pax5 directly represses transcription of Notch1, thereby blocking T cell development; pan-hematopoietic Pax5 expression strongly promoted B cell development at the expense of T lymphopoiesis but did not block myeloid development. Ikaros-locus knockin of Pax5 minigene, conditional/constitutive activation, flow cytometry, gene expression analysis Immunity High 12479824
2002 Pax5 interacts with Daxx via the partial homeodomain of Pax5 and C-terminal fragment of Daxx; this interaction can result in either transcriptional corepression or coactivation in B cells; coactivation involves recruitment of CBP (co-precipitated in complexes containing Pax5, Daxx, and CBP). Yeast two-hybrid, transient transfection reporter assays, co-immunoprecipitation The Journal of biological chemistry Medium 11799127
2002 Early B cell factor (EBF), E2A, and Pax-5 cooperate to activate the mb-1 promoter: in vivo footprinting showed occupancy of EBF, E-box, and Pax-5 binding sites; EBF and E2A synergistically activated the promoter in non-B cells, and Pax-5 (with Ets partners) is required at all mb-1-expressing stages. In vivo footprinting, transient transfection reporter assays, DNA microarray expression analysis Molecular and cellular biology Medium 12446773
2003 CD40 stimulation induces nuclear translocation of APE/Ref-1, which then modulates DNA-binding activity of Pax5a/BSAP and EBF in activated B cells; repression of APE/Ref-1 blocks CD40-mediated Pax5a activation; Pax5a physically interacts with EBF and enhances EBF DNA-binding activity. Co-immunoprecipitation, EMSA, nuclear fractionation, transient transfection reporter assay, siRNA knockdown of Ref-1 The Journal of biological chemistry Medium 14594818
2003 Mutations in the β-hairpin/β-turn of the Pax-5 paired domain DNA-binding domain reduce DNA sequence recognition and mb-1 transcription activation; specific amino acids contacting Ets-1 in the crystal structure are required for Ets recruitment and mb-1 transcription; mutation Q22A selectively abolishes Fli-1 recruitment without affecting GABPα recruitment. Crystal structure-guided mutagenesis, cell-based transcription assay, in vitro EMSA Nucleic acids research High 14500810
2004 Pax5 induces large-scale contraction of the IgH locus and distal VH-DJH rearrangements; reconstitution of Pax5 in Pax5-/- pro-B cells is sufficient to trigger locus contraction and distal VH-DJH recombination; ectopic Pax5 in thymocytes induces only proximal VH-DJH rearrangements (no locus contraction), indicating a pro-B-specific cofactor is required. Retroviral Pax5 reconstitution in Pax5-/- pro-B cells, 3D FISH locus contraction assay, VDJ recombination PCR, Ikaros-Pax5 knockin thymocyte analysis Genes & development High 15004008
2004 Pax-5 directly activates kappa sterile transcription and is required for Ig kappa chain gene rearrangement; the transactivation domain of Pax-5 is required for this function; in Pax5-deficient pre-BI cells the Jκ locus localizes to the nuclear periphery (repressive compartment), and Pax5 expression repositions it and enables rearrangement. Hormone-inducible Pax5 reconstitution in Pax5-/- pre-BI cells, RT-PCR, FISH nuclear localization assay Journal of immunology High 15067064
2006 Pax5 directly binds multiple sites in VH gene coding regions in vitro and occupies VH genes in early B lineage cells in vivo; Pax5 physically interacts with the RAG1-RAG2 complex to enhance RAG-mediated VH recombination signal sequence cleavage and recombination of a VH gene substrate. ChIP, EMSA, co-immunoprecipitation (Pax5–RAG1/RAG2), in vitro V(D)J recombination assay Nature immunology High 16680144
2006 Deletion of Pax5 in Pax5-deficient DT40 B cells leads to loss of BCR signaling, upregulation of Blimp-1 and XBP-1, downregulation of Bcl-6, and elevated IgM secretion, demonstrating that Pax5 represses plasma cell differentiation; restoration of Pax5 expression normalizes this transcriptional program. Gene targeting (Pax5 deletion in DT40), rescue by Pax5 re-expression, RT-PCR, IgM secretion assay, BCR signaling assay Immunity High 16546097
2007 Pax5 in B lymphomas maintains expression of BCR signaling components (including CD79a/Igα) while repressing ITAM antagonists CD22 and PIR-B; Pax5-dependent BCR/ITAM signaling promotes neoplastic growth, as shown by dominant-negative Pax5 and Pax5 knockdown reducing lymphoma cell expansion. Tamoxifen-inducible Pax5-ER fusion protein, dominant-negative Pax5, shRNA knockdown, expression profiling, Syk inhibitor pharmacology The Journal of clinical investigation High 17717600
2007 BSAP/Pax5 directly binds Wp (Epstein-Barr virus transforming promoter) on the viral genome in transformed B cells (ChIP); mutation of BSAP binding sites in recombinant EBV completely abolishes Wp activity and outgrowth of transformed cells in B cells, while EBV entry into epithelial cells is unaffected. Chromatin immunoprecipitation (ChIP) on viral genome, recombinant EBV with Wp BSAP binding site mutations Journal of virology High 17626071
2007 BSAP/PAX5 directly represses PRDM1 (Blimp1) transcription by binding to its promoter in vivo, forming an autoregulatory negative-feedback loop that maintains B cell identity and restrains plasma cell differentiation. EMSA, ChIP, ectopic BSAP expression with PRDM1 promoter reporter (including BSAP binding site mutant) Blood High 17682124
2000 The nuclear localization of BSAP/Pax5 is mediated by a defined NLS sequence (NKRKRDE, amino acids 195–201) in the central domain that binds importin alpha1 (Rch1); this NLS was confirmed by yeast two-hybrid, GST pulldown, and by conferring nuclear localization on GFP fusion proteins. Yeast two-hybrid, GST pulldown, GFP-fusion nuclear localization assay, mutagenesis The Journal of biological chemistry High 10748034
2011 PAX5 fusion leukemia proteins act as dominant-negatives by multimerizing their DNA-binding domains (via partner-derived oligomerization sequences), resulting in extremely stable chromatin binding (measured by FRAP) and competition with wild-type PAX5 for target sites; tetramerization (not corepressor-binding motifs) is necessary and sufficient for dominant-negative activity. FRAP in living cells, in vitro DNA binding assays, domain deletion/mutagenesis, artificial dimerization/trimerization/tetramerization domain fusions Oncogene High 21765475
2011 PAX5-PML fusion protein acts as dual dominant-negative for both PAX5 and PML: it inhibits PAX5 transcriptional activity and suppresses PAX5 target gene expression (despite retaining PAX5 DBD, it binds promoters through association with endogenous PAX5 rather than direct DNA binding); it also disrupts PML nuclear bodies, inhibits PML sumoylation, and confers apoptosis resistance reversible by arsenic trioxide. Luciferase reporter assay, ChIP, co-immunoprecipitation, sumoylation assay, PML-NB immunofluorescence, apoptosis assay Oncogene Medium 21217775
2013 SOX11 directly binds the PAX5 locus (identified by ChIP-microarray) and regulates PAX5 expression; SOX11 knockdown downregulates PAX5, induces BLIMP1 expression, and promotes plasmacytic differentiation in MCL cells. ChIP-microarray, siRNA knockdown, gene expression profiling, flow cytometry Blood Medium 23321250
2015 EBV noncoding RNA EBER2 directly interacts with PAX5 protein and is required for PAX5 localization to the terminal repeats of the latent EBV genome; this recruitment is mediated by base-pairing between EBER2 and nascent transcripts from the terminal repeat locus; EBER2 knockdown phenocopies PAX5 depletion in upregulating LMP2A/B and LMP1. CHART (Capture Hybridization Analysis of RNA Targets), co-immunoprecipitation (EBER2–PAX5), EBER2 knockdown, reporter/ChIP assays Cell High 25662012
2018 In human primordial germ cell (hPGC) development, PAX5 forms a core transcriptional network with OCT4 and PRDM1; PAX5 switches OCT4 from its pluripotency partner SOX2 to drive germline specification; PAX5 acts upstream of OCT4 and PRDM1 by epistasis; PAX5 loss-of-function impairs hPGC development. ChIP-seq (OCT4 occupancy in hPGCs vs hESCs), gain- and loss-of-function (genome editing), epistasis analysis, in vitro differentiation and xenograft engraftment Nature cell biology High 29713018
2019 The PAX5 p.Pro80Arg mutation impairs B lymphoid development and promotes B-ALL with biallelic PAX5 alteration in vivo, demonstrating a gain-of-leukemogenic function for this specific missense mutation. In vivo mouse model with PAX5 P80R knockin, B cell developmental assays, B-ALL disease induction Nature genetics High 30643249
2021 Pax5 restrains PTEN protein expression at the posttranscriptional level (likely through Pten-targeting microRNAs), thereby promoting PI3K-AKT signaling in mature B cells; Pax5-deficient follicular B cells fail to proliferate upon BCR or TLR stimulation due to increased PTEN and impaired PI3K signaling; additional PTEN loss in Pten,Pax5 double-mutant mice rescues follicular and marginal zone B cell numbers but not germinal center formation. Conditional knockout mouse (Pax5 deletion in peripheral B cells), Pten/Pax5 double-mutant mice, Western blot (PTEN protein), PI3K-AKT signaling assays, B cell stimulation/proliferation assays Science immunology High 34301800
2021 EBF1 and PAX5 bind opposing regulatory elements in the Myc locus and regulate Myc in an opposing manner: EBF1 activates Myc expression (critical for pro-B cell expansion) while ectopic PAX5 in EBF1-deficient cells inhibits cell cycle and reduces Myc expression; Pax5 inactivation reduces EBF1 requirements for pro-B cell expansion. Chromosome conformation analysis, ATAC-seq, ChIP-seq, CRISPR-Cas9 targeting of EBF1-binding sites, reporter assay, conditional KO mouse Blood High 33619557
2022 PAX5 acts as a key activator of CD58 expression at the CD58 locus through an epigenetically defined enhancer; the PAX5 P80R mutation disrupts this enhancer, reducing CD58 expression and conferring blinatumomab resistance in B-ALL. Genome-wide CRISPR screen, transcription factor screen (1639 TFs), genome editing (P80R mutation), ChIP/ATAC-seq at CD58 locus Science advances High 36516256
2022 The PAX5-JAK2 fusion protein functions as a nuclear driver of B-ALL: its DNA-binding function (via PAX5 DBD) and kinase activity (via JAK2 domain) are both required for leukemogenesis; PAX5-JAK2 phosphorylates STAT5 in the nucleus, sustaining high levels of active nuclear pSTAT5 and STAT5 target gene expression. Endogenous locus Pax5-Jak2 knockin mouse, domain-specific mutagenesis (kinase-dead, DNA-binding mutants), phospho-STAT5 Western blot/ChIP, RNA-seq The EMBO journal High 35156727
2022 Biallelic loss-of-function mutations in PAX5 cause hypogammaglobulinemia (due to early B cell developmental block), defective immune responses, aberrant cerebellar foliation, hypoplasia of the substantia nigra and ventral tegmental area (loss of GABAergic neurons), and ASD-like behavioral deficits; lineage tracing identifies Pax5 as a crucial regulator of cerebellar morphogenesis and midbrain GABAergic neurogenesis. Patient-specific Pax5 knockin mouse, flow cytometry, behavioral testing, histology/lineage tracing, immune response assays The Journal of experimental medicine High 35947077
2024 Acute in vivo degradation of Pax5 protein in pro-B, small pre-B, and immature B cells revealed that Pax5 functions predominantly as a transcriptional activator by inducing open chromatin at target genes; Pax5 directly activates Rag1, Rag2, Dntt, Irf4, and Irf8 (contributing to V(D)J recombination); Pax5, like Ebf1, represses the cohesin-release factor Wapl to mediate prolonged loop extrusion across the Igh locus; Pax5 co-activates Igll1 and Vpreb1 surrogate light-chain genes in pro-B cells. Acute protein degradation (dTAG system) in mice, ATAC-seq, ChIP-seq, RNA-seq across multiple B cell developmental stages Nature immunology High 39179932
2009 PAX5 directly regulates c-Met transcription in small-cell lung cancer (SCLC) cells; PAX5 binds the c-Met promoter (shown by luciferase reporter and ChIP); phospho-c-Met and PAX5 co-localize in the nucleus and physically interact; PAX5 knockdown decreases SCLC cell viability, especially with c-Met or topoisomerase inhibitors. Luciferase reporter assay, ChIP, co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown + drug treatment Laboratory investigation Medium 19139719
2020 Repression of Pax5 by Blimp1 is NOT required for plasma cell development; mice expressing a Pax5 minigene ectopically in plasma cells (IghPax5/+) still efficiently develop plasma cells and secrete antibodies, though IgG secretion is modestly decreased and long-lived plasma cells are reduced in older mice. IghPax5/+ knockin mouse (Pax5 minigene expressed from IgH locus), plasma cell development analysis, antibody secretion assays The Journal of experimental medicine High 32780801

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1994 Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 667 8001127
2007 Pax5: the guardian of B cell identity and function. Nature immunology 511 17440452
1992 Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes & development 484 1516825
2019 PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature genetics 472 30643249
1997 Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes & development 329 9042861
2004 Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. Genes & development 325 15004008
1992 The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Molecular and cellular biology 297 1375324
1995 DNA-binding and transactivation properties of Pax-6: three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5). Molecular and cellular biology 252 7739566
1998 Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. The EMBO journal 248 9545244
2000 Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family. The EMBO journal 212 10811620
1996 Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes & development 203 8804314
2001 Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 196 11420047
2011 Pax5: a master regulator of B cell development and leukemogenesis. Advances in immunology 191 21970955
2002 Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 180 12479824
2006 Loss of Pax5 promotes plasma cell differentiation. Immunity 171 16546097
1997 Cooperation of Pax2 and Pax5 in midbrain and cerebellum development. Proceedings of the National Academy of Sciences of the United States of America 144 9159136
1996 C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8. The EMBO journal 133 8617244
1994 The B cell-specific transcription factor BSAP regulates B cell proliferation. The Journal of experimental medicine 132 7511679
2015 EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA. Cell 130 25662012
2013 SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 119 23321250
1995 Deregulated expression of PAX5 in medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America 119 7777574
1998 Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 115 9694719
2002 The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells. The Journal of biological chemistry 97 11799127
1996 An interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J chain gene. Immunity 94 8885870
2009 PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory investigation; a journal of technical methods and pathology 90 19139719
2000 An 'environment to nucleus' signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. Nucleic acids research 87 10666449
1997 Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. Journal of immunology (Baltimore, Md. : 1950) 83 9120274
1995 Pax5 (BSAP) regulates the murine immunoglobulin 3' alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. Proceedings of the National Academy of Sciences of the United States of America 83 7777508
2002 Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter. Molecular and cellular biology 82 12446773
2003 The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. American journal of clinical pathology 80 14608905
2001 Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. International reviews of immunology 74 11342298
2011 The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer research 68 22127921
1995 The role of BSAP (Pax-5) in B-cell development. Current opinion in genetics & development 67 8664547
2006 Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes. Nature immunology 60 16680144
2021 DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica 56 32646889
1997 The Pax-5 gene is alternatively spliced during B-cell development. The Journal of biological chemistry 56 9092562
1994 The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription. Journal of immunology (Baltimore, Md. : 1950) 56 8144891
2019 PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia 55 30842609
1999 The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. Cancer research 55 10197586
1998 Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Seminars in immunology 55 9618759
1999 AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. The Journal of biological chemistry 54 10455134
1997 The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human epsilon germline promoter. Journal of immunology (Baltimore, Md. : 1950) 53 9190940
1995 BSAP: a key regulator of B-cell development and differentiation. Immunology today 53 8579748
2021 Pax5 regulates B cell immunity by promoting PI3K signaling via PTEN down-regulation. Science immunology 51 34301800
2000 BSAP can repress enhancer activity by targeting PU.1 function. Molecular and cellular biology 50 10688639
2007 Diagnostic uses of Pax5 immunohistochemistry. Advances in anatomic pathology 49 17717432
2000 The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. Journal of virology 49 11044090
1997 Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 49 9442394
1998 Dependence of BSAP repressor and activator functions on BSAP concentration. Science (New York, N.Y.) 47 9506950
2006 Pax-5 expression in nonhematopoietic tissues. American journal of clinical pathology 46 17050077
2003 Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development. Blood 45 12560221
2002 Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 45 12453881
2017 Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis. Journal of immunology (Baltimore, Md. : 1950) 42 28978690
1996 Altered expression of Pax-5 gene in human myeloma cells. Blood 41 8639790
2021 Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. Blood advances 40 34547766
2003 CD40 stimulation induces Pax5/BSAP and EBF activation through a APE/Ref-1-dependent redox mechanism. The Journal of biological chemistry 38 14594818
2022 PAX5 alterations in B-cell acute lymphoblastic leukemia. Frontiers in oncology 37 36387144
2002 Roles of EBF and Pax-5 in B lineage commitment and development. Seminars in immunology 37 12457614
1999 Monoallelic expression of Pax5: a paradigm for the haploinsufficiency of mammalian Pax genes? Biological chemistry 37 10430025
1999 BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage. Blood 37 10572073
2011 Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 36 21765475
2011 PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 35 21217775
2007 Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. Journal of virology 35 17626071
2007 B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. The Journal of clinical investigation 35 17717600
2004 Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 35 15195108
2018 A PAX5-OCT4-PRDM1 developmental switch specifies human primordial germ cells. Nature cell biology 34 29713018
2003 Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP). Nucleic acids research 34 14500810
1998 Early function of Pax5 (BSAP) before the pre-B cell receptor stage of B lymphopoiesis. The Journal of experimental medicine 34 9705955
2010 Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Archives of pathology & laboratory medicine 33 21043826
1998 Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. British journal of haematology 33 9722295
1996 B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development. Journal of immunology (Baltimore, Md. : 1950) 33 8786288
2021 EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene. Blood 32 33619557
2021 DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway. International journal of biological sciences 30 33613108
2007 Human BSAP and BLIMP1 conform an autoregulatory feedback loop. Blood 30 17682124
2022 The MBNL1/circNTRK2/PAX5 pathway regulates aerobic glycolysis in glioblastoma cells by encoding a novel protein NTRK2-243aa. Cell death & disease 29 36064939
2004 Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. Blood 29 15561888
1998 Overexpression of BSAP/Pax-5 inhibits switching to IgA and enhances switching to IgE in the I.29 mu B cell line. Journal of immunology (Baltimore, Md. : 1950) 29 9743352
2018 PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America 28 30257940
2002 Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. British journal of haematology 28 11841448
2022 PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Science advances 27 36516256
2000 BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence. The Journal of biological chemistry 27 10748034
2017 Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes. Oncotarget 26 28076843
2007 Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 26 17431414
2003 Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. Journal of Korean medical science 26 14676435
1999 Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leukemia & lymphoma 25 10350329
2022 The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation. The EMBO journal 24 35156727
2022 Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder. The Journal of experimental medicine 24 35947077
2020 Repression of the B cell identity factor Pax5 is not required for plasma cell development. The Journal of experimental medicine 24 32780801
2020 EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism. Genes & development 24 33004416
2006 Pax5--a critical inhibitor of plasma cell fate. Scandinavian journal of immunology 24 16918686
2004 Pax-5 is essential for kappa sterile transcription during Ig kappa chain gene rearrangement. Journal of immunology (Baltimore, Md. : 1950) 24 15067064
2022 The Pleiotropy of PAX5 Gene Products and Function. International journal of molecular sciences 23 36077495
2002 DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Molecular immunology 23 12044782
2018 Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation. Anticancer research 22 30194145
2008 PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens. American journal of clinical pathology 22 18343782
1999 The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU international 22 10368252
2024 Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development. Nature immunology 21 39179932
2015 LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. Oncotarget 21 25595912
2012 PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. Histopathology 21 23163626
2005 Deficient B lymphopoiesis in murine senescence: potential roles for dysregulation of E2A, Pax-5, and STAT5. Seminars in immunology 21 15967678

Missed literature

Know a paper Affinage missed for PAX5? Flag it for the maintainers and the community.

No submissions yet.